SCHEMBL2661041

SCHEMBL2661041

COc1ccc(CN2Cc3nc4c(-c5cc(F)ccc5C)cccc4c(N)c3C2=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ P2RX7 Q99572 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ WDR5 P61964 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRL1 P41146 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ PIK3R1 P27986 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ PDE5A O76074 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ PRMT5 O14744 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656179 0.92 LMNA (0.39) LMNAHTTNPSR1MAPTP2RX7
SCHEMBL2661185 0.92 GABRG2 (0.39) LMNAHTTNPSR1MAPTKDM4E
SCHEMBL2660724 0.90 MAPT (0.39) LMNAHTTNPSR1MAPTKDM4E
SCHEMBL2661184 0.88 KDM4E (0.39) LMNAHTTNPSR1KDM4EMEN1
SCHEMBL2661670 0.87 KDM4E (0.39) LMNAHTTNPSR1MAPTKDM4E
SCHEMBL2661180 0.85 PDE5A (0.37) LMNAHTTNPSR1MAPTKDM4E
SCHEMBL2660778 0.85 MAPT (0.40) LMNAHTTNPSR1MAPTKDM4E
SCHEMBL2658694 0.85 GABRA1 (0.43) LMNAHTTNPSR1KDM4EMEN1
SCHEMBL2661248 0.84 GABRG2 (0.45) KDM4EMEN1KMT2ACHRM5PDE5A
SCHEMBL2661222 0.84 CRHR1 (0.42) MAPTKDM4EMEN1KMT2ACHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF LMNA 1909/4885HTT 503/4885NPSR1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback